MEIP MEI PHARMA INC Contract Awards 8-K Filing 2023 - Contract Cancelled MEI Pharma, Inc. has terminated its License, Development, and Commercialization Agreement with Kyowa Kirin Co., Ltd., thereby regaining full global rights to develop, manufacture, and commercialize ME-401, a potential therapeutic.Get access to all SEC 8-K filings of the MEI PHARMA INC